Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 4.713
Filter
1.
BMC Infect Dis ; 24(1): 981, 2024 Sep 16.
Article in English | MEDLINE | ID: mdl-39285366

ABSTRACT

BACKGROUND: Mycoplasma genitalium (MG), a sexually transmitted infection (STI), has emerged as a common cause of non-gonococcal urethritis and cervicitis worldwide, with documented resistance to commonly used antibiotics including doxycycline and azithromycin. Data in Ghana regarding the prevalence of MG is limited. METHODS: This retrospective study investigated MG presence and macrolide resistance among patients who previously reported to selected clinics for STI symptoms between December 2012 and June 2020. Samples were screened for MG and mutations associated with azithromycin resistance were investigated using Nucleic Acid Amplification Testing (NAAT) including the Resistance Plus MG® kit from SpeeDx and the LightMix® kit for MG, combined with the Modular Mycoplasma Macrolide from TIB Molbiol. RESULTS: A total of 1,015 samples were screened, out of which MG infection rate by TIB Molbiol and SpeeDx were 3.1% and 3.4%, respectively. The mutation responsible for macrolide resistance was detected in one MG positive sample by both assays. Both diagnostic tests revealed no significant association between MG infection and socio-demographic characteristics, clinical symptoms, gonorrhea, and chlamydia infection status. There was no significant difference in the mycoplasma percentage positivity rate detected using SpeeDx (3.4%) and TIB Molbiol (3.1%). CONCLUSIONS: While not commonly tested as a cause of STI symptoms, MG is widespread in Ghana, exhibiting symptoms and prevalence comparable to those in other countries and linked to antimicrobial resistance. Future research using various molecular techniques is essential to monitor resistance trends and guide future antibiotic choices.


Subject(s)
Anti-Bacterial Agents , Drug Resistance, Bacterial , Macrolides , Mycoplasma Infections , Mycoplasma genitalium , Mycoplasma genitalium/drug effects , Mycoplasma genitalium/genetics , Mycoplasma genitalium/isolation & purification , Humans , Mycoplasma Infections/epidemiology , Mycoplasma Infections/drug therapy , Mycoplasma Infections/microbiology , Ghana/epidemiology , Female , Male , Adult , Retrospective Studies , Prevalence , Macrolides/pharmacology , Macrolides/therapeutic use , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Drug Resistance, Bacterial/genetics , Young Adult , Adolescent , Middle Aged , Sexual Health , Azithromycin/pharmacology , Azithromycin/therapeutic use , Mutation , Microbial Sensitivity Tests
2.
Traffic ; 25(9): e12956, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39313937

ABSTRACT

Limited nutrient availability in the tumor microenvironment can cause the rewiring of signaling and metabolic networks to confer cancer cells with survival advantages. We show here that the limitation of glucose, glutamine and serum from the culture medium resulted in the survival of a population of cancer cells with high viability and capacity to form tumors in vivo. These cells also displayed a remarkable increase in the abundance and size of lysosomes. Moreover, lysosomes were located mainly in the perinuclear region in nutrient-limited cells; this translocation was mediated by a rapid post-transcriptional increase in the key endolysosomal trafficking protein Rab7a. The acidic lysosomes in nutrient-limited cells could trap weakly basic drugs such as doxorubicin, mediating resistance of the cells to the drug, which could be partially reversed with the lysosomal inhibitor bafilomycin A1. An in vivo chorioallantoic membrane (CAM) assay indicated a remarkable decrease in microtumor volume when nutrient-limited cells were treated with 5-Fluorouracil (5-FU) and bafilomycin A1 compared to cells treated with either agent alone. Overall, our data indicate the activation of complementary pathways with nutrient limitation that can enable cancer cells to survive, proliferate and acquire drug resistance.


Subject(s)
Drug Resistance, Neoplasm , Lysosomes , Macrolides , rab GTP-Binding Proteins , rab7 GTP-Binding Proteins , Lysosomes/metabolism , Humans , rab7 GTP-Binding Proteins/metabolism , Drug Resistance, Neoplasm/genetics , rab GTP-Binding Proteins/metabolism , rab GTP-Binding Proteins/genetics , Macrolides/pharmacology , Nutrients/metabolism , Cell Line, Tumor , Fluorouracil/pharmacology , Animals , Doxorubicin/pharmacology , Neoplasms/metabolism , Neoplasms/genetics , Neoplasms/pathology , Neoplasms/drug therapy
3.
Pestic Biochem Physiol ; 204: 106058, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39277374

ABSTRACT

The juvenile hormone binding protein (JHBP) and takeout (TO) genes, mediated by the juvenile hormone (JH), play a crucial role in regulating the reproductive physiology of insects. Our previous study revealed that spinosad-resistant Frankliniella occidentalis (NIL-R) exhibited reduced fecundity and significant changes in JHBP/TO family gene expression. We hypothesized that these genes were involved in regulating the fitness costs associated with resistance. In this study, 45 JHBP/TO genes were identified in F. occidentalis, among which FoTO2 and FoTO10 were duplicates. Additionally, eight genes exhibited significant down-regulation in the NIL-R population. Two genes (FoTO6 and FoTO24) that exhibited the most significant differential expression between the spinosad-susceptible (Ivf03) and NIL-R populations were selected to investigate their roles in resistance fitness using RNA interference (RNAi). Following interference with FoTO6, FoTO24, and their combination, the expression levels of vitellogenin (Vg) were downregulated by 3%-30%, 13%-28%, and 14%-32% from the 2nd day to the 5th day, respectively; Krüppel-homolog 1 (Kr-h1) expression was down-regulated by 3%-65%, 11%-34%, and 11%-39% from the 2nd day to the 5th day, respectively; ovariole length was shortened by approximately 18%, 21%, and 24%, respectively; and the average number of eggs decreased from 407 to 260, 148, and 106, respectively. Additionally, a JH supplementation experiment on the NIL-R population revealed that the expression levels of both FoTO6, FoTO24, Vg and Kr-h1 were significantly upregulated compared with those observed in the Ivf03 population, resulting in increased fecundity. These results suggest that FoTO6 and FoTO24 are involved in JH-mediated regulation of the reproductive fitness cost of resistance to spinosad. Further, FoTO6 and FoTO24 can be considered potential target genes for applying RNAi technology in the scientific management of F. occidentalis.


Subject(s)
Insect Proteins , Insecticide Resistance , Thysanoptera , Animals , Insecticide Resistance/genetics , Insect Proteins/genetics , Insect Proteins/metabolism , Thysanoptera/genetics , Thysanoptera/physiology , Thysanoptera/drug effects , Insecticides/pharmacology , Female , Reproduction/genetics , Macrolides/pharmacology , Vitellogenins/genetics , Vitellogenins/metabolism , Drug Combinations , Juvenile Hormones/metabolism , Juvenile Hormones/pharmacology , RNA Interference , Carrier Proteins/genetics , Carrier Proteins/metabolism , Genetic Fitness
4.
Mar Drugs ; 22(9)2024 Sep 20.
Article in English | MEDLINE | ID: mdl-39330307

ABSTRACT

Marine natural products comprise unique chemical structures and vast varieties of biological activities. This review aims to summarize halichondrin, a marine natural product, and its synthetic analogs along with its therapeutic properties and mechanisms. Halichondrin and its analogs, derived from marine sponges, exhibit potent antineoplastic properties, making them promising candidates for cancer therapeutics. These compounds, characterized by their complex molecular structures, have demonstrated significant efficacy in inhibiting microtubule dynamics, leading to cell cycle arrest and apoptosis in various cancer cell lines. Several types of halichondrins such as halichondrins B, C, norhalichondrin B, and homohalichondrin B have been discovered with similar anticancer and antitumor characteristics. Since naturally available halichondrins show hurdles in synthesis, recent advancements in synthetic methodologies have enabled the development of several halichondrin analogs, such as E7389 (eribulin), which have shown improved therapeutic indices. Eribulin has shown excellent immunomodulatory properties by several mechanisms such as reprogramming tumor microenvironments, facilitating the infiltration and activation of immune cells, and inhibiting microtubule dynamics. Despite promising results, challenges remain in the synthesis and clinical application of these compounds. This review explores the mechanisms underlying the immunomodulatory activity of halichondrin and its analogs in cancer therapy, along with their clinical applications and potential for future drug development.


Subject(s)
Antineoplastic Agents , Porifera , Animals , Porifera/chemistry , Humans , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemistry , Neoplasms/drug therapy , Biological Products/pharmacology , Biological Products/chemistry , Furans/pharmacology , Furans/chemistry , Furans/isolation & purification , Aquatic Organisms , Ketones/pharmacology , Ketones/chemistry , Ketones/isolation & purification , Immunologic Factors/pharmacology , Immunologic Factors/chemistry , Immunologic Factors/isolation & purification , Immunomodulating Agents/pharmacology , Immunomodulating Agents/chemistry , Immunomodulating Agents/isolation & purification , Macrolides/pharmacology , Macrolides/chemistry , Polyether Polyketides , Ethers, Cyclic
5.
J Nat Prod ; 87(9): 2327-2334, 2024 Sep 27.
Article in English | MEDLINE | ID: mdl-39258410

ABSTRACT

Two sulfur-containing heterodimers of a cytochalasan and a macrolide, sucurchalasins A and B (1 and 2), and four known cytochalasan monomers (3-6), as well as four known macrolide derivatives (7-10), were obtained from the endophytic fungus Aspergillus spelaeus GDGJ-286. Sucurchalasins A and B (1 and 2) are the first cytochalasan heterodimers formed via a thioether bridge between cytochalasan and curvularin macrolide units. Their structures were elucidated by detailed analysis of NMR, LC-MS/MS, and X-ray crystallography. In bioassays, 1 and 2 exhibited cytotoxic effects on A2780 cells, with IC50 values of 3.9 and 8.3 µM, respectively. They also showed antibacterial activities against E. faecalis and B. subtilis with MIC values of 3.1 and 6.3 µg/mL, respectively.


Subject(s)
Aspergillus , Cytochalasins , Macrolides , Aspergillus/chemistry , Cytochalasins/pharmacology , Cytochalasins/chemistry , Cytochalasins/isolation & purification , Macrolides/pharmacology , Macrolides/chemistry , Molecular Structure , Humans , Microbial Sensitivity Tests , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Sulfur/chemistry , Crystallography, X-Ray , Bacillus subtilis/drug effects
6.
Toxicol In Vitro ; 100: 105920, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39173682

ABSTRACT

Triple-negative breast cancer (TNBC) is highly aggressive and metastatic in nature. Existing treatment modalities for TNBC are associated with severe side effects. Thioredoxin reductase (TRXR), the pivotal component of the thioredoxin system, remains overexpressed in various cancer cells including TNBC; promotes cell growth, proliferation, and metastasis, and inhibits apoptosis. Pestalotioprolide E is one of the potent macrolides, a class of secondary metabolites derived from an endophytic fungus Pestalotiopsis microspora with relatively unexplored biological activities. Our study revealed increased expression and activity of TRXR1 in MDA-MB-231 cells compared to the non-cancerous cells. In silico docking analysis and in vitro activity assay demonstrated that Pestalotioprolide E directly interacts with TRXR1 and inhibits its enzymatic activity. This inhibition induces apoptosis via TRX1/ASK1/P38MAPK death signaling cascade and retards metastasis through modulating VEGF, MMP-2, MMP-9, E-cadherin, N-cadherin in MDA-MB-231 cells. Taken together present study establishes TRXR1 as a molecular target for Pestalotioprolide E and its anticancer effect can be attributed to the inhibition of TRXR1 activity in MDA-MB-231.


Subject(s)
Antineoplastic Agents , Apoptosis , MAP Kinase Kinase Kinase 5 , Macrolides , Signal Transduction , Thioredoxin Reductase 1 , Thioredoxins , Triple Negative Breast Neoplasms , Humans , Triple Negative Breast Neoplasms/drug therapy , Triple Negative Breast Neoplasms/metabolism , Triple Negative Breast Neoplasms/pathology , Cell Line, Tumor , Antineoplastic Agents/pharmacology , Macrolides/pharmacology , Thioredoxin Reductase 1/metabolism , Thioredoxin Reductase 1/genetics , Signal Transduction/drug effects , Thioredoxins/metabolism , Thioredoxins/genetics , Apoptosis/drug effects , MAP Kinase Kinase Kinase 5/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism , Molecular Docking Simulation , Cell Movement/drug effects , Female
7.
Biomedica ; 44(2): 182-190, 2024 05 30.
Article in English, Spanish | MEDLINE | ID: mdl-39088528

ABSTRACT

Introduction: The Mycobacterium chelonae species and the M. avium and M. abscessus complexes are emerging pathogens that cause mycobacteriosis. Treatment depends on the species and subspecies identified. The drugs of choice are macrolides and aminoglycosides. However, due to the resistance identified to these drugs, determining the microbe's sensitivity profile will allow clinicians to improve the understanding of the prognosis and evolution of these pathologies. Objective: To describe the macrolide and aminoglycoside susceptibility profile of cultures identified by Colombia's Laboratorio Nacional de Referencia de Mycobacteria from 2018 to 2022, as Mycobacterium avium complex, M. abscessus complex, and M. chelonae. Materials and methods. This descriptive study exposes the susceptibility profile to macrolides and aminoglycosides of cultures identified as M. avium complex, M. abscessus complex, and M. chelonae using the GenoType® NTM-DR method. Materials and methods: This descriptive study exposes the susceptibility profile to macrolides and aminoglycosides of cultures identified as M. avium complex, M. abscessus complex, and M. chelonae using the GenoType® NTM-DR method. Results: We identified 159 (47.3 %) cultures as M. avium complex, of which 154 (96.9 %) were sensitive to macrolides, and 5 (3.1 %) were resistant; all were sensitive to aminoglycosides. From the 125 (37.2 %) cultures identified as M. abscessus complex, 68 (54.4 %) were sensitive to macrolides, 57 (45.6 %) were resistant to aminoglycosides, and just one (0.8 %) showed resistance to aminoglycosides. The 52 cultures (15.5 %) identified as M. chelonae were sensitive to macrolides and aminoglycosides. Conclusions: The three studied species of mycobacteria have the least resistance to Amikacin. Subspecies identification and their susceptibility profiles allow the establishment of appropriate treatment schemes, especially against M. abscessus.


Introducción. Mycobacterium chelonae y los complejos Mycobacterium avium y M. abscessus, son agentes patógenos emergentes causantes de micobacteriosis. El tratamiento de esta infección depende de la especie y la subespecie identificadas. Los fármacos de elección son los macrólidos y aminoglucósidos, contra los cuales se ha reportado resistencia; por esta razón, el determinar el perfil de sensibilidad le permite al médico tratante comprender mejor el pronóstico y la evolución de estas infecciones. Objetivo. Describir los perfiles de sensibilidad ante macrólidos y aminoglucósidos, de los cultivos identificados como complejo Mycobacterium avium, complejo M. abscessus o especie M. chelonae, en el Laboratorio Nacional de Referencia de Micobacterias durante los años 2018 a 2022. Materiales y métodos. Se llevó a cabo un estudio descriptivo del perfil de sensibilidad a macrólidos y aminoglucósidos, de los cultivos identificados como complejo M. avium, complejo M. abscessus o M. chelonae, mediante la metodología GenoType® NTM-DR. Resultados. Los cultivos del complejo M. avium fueron 159 (47,3 %), de los cuales, 154 (96,9 %) fueron sensibles y 5 (3,1 %) resistentes a los macrólidos; todos fueron sensibles a los aminoglucósidos. Del complejo M. abscessus se estudiaron 125 (37,2 %) cultivos, 68 (54,4 %) resultaron sensibles y 57 (45,6 %) resistentes a los macrólidos; solo un cultivo (0,8 %) fue resistente a los aminoglucósidos. De M. chelonae se analizaron 52 cultivos (15,5 %), todos sensibles a los macrólidos y aminoglucósidos. Conclusiones. En las tres especies de micobacterias estudiadas, la resistencia contra la amikacina fue la menos frecuente. La identificación de las subespecies y los perfiles de sensibilidad permiten instaurar esquemas de tratamiento adecuados, especialmente en las micobacteriosis causadas por M. abscessus.


Subject(s)
Aminoglycosides , Macrolides , Microbial Sensitivity Tests , Mycobacterium Infections, Nontuberculous , Mycobacterium abscessus , Mycobacterium avium Complex , Mycobacterium chelonae , Macrolides/pharmacology , Mycobacterium abscessus/drug effects , Mycobacterium abscessus/genetics , Mycobacterium abscessus/isolation & purification , Colombia/epidemiology , Mycobacterium chelonae/drug effects , Mycobacterium chelonae/genetics , Mycobacterium chelonae/isolation & purification , Aminoglycosides/pharmacology , Humans , Mycobacterium avium Complex/drug effects , Mycobacterium avium Complex/genetics , Mycobacterium avium Complex/isolation & purification , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium Infections, Nontuberculous/epidemiology , Mycobacterium Infections, Nontuberculous/drug therapy , Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Prevalence , Drug Resistance, Multiple, Bacterial
8.
J Glob Antimicrob Resist ; 38: 368-375, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39117142

ABSTRACT

BACKGROUND: Macrolides inhibit the growth of bacterial cells by preventing the elongation of polypeptides during protein biosynthesis and include natural, synthetic, and semi-synthetic products. Elongation prevention occurs by blocking the passage of the polypeptide chain as the macrolides bind at the nascent peptide exit tunnel. OBJECTIVE: Recent data of ribosome profiling via ribo-seq further proves that, other than blocking the polypeptide chain, macrolides are also able to affect the synthesis of individual proteins. Thus, this shows that the mode of action of macrolides is more complex than we initially thought. Since the discovery of macrolides in the 1950s, they have been widely used in veterinary practice, agriculture, and medicine. Due to misuse and overuse of antibiotics, bacteria have acquired resistance against them. Hence, it is of utmost importance for us to fully understand the mode of action of macrolides as well as the mechanisms of resistance against macrolides in order to mitigate antibiotic-resistance issues. RESULTS: Chemical modifications can be performed to improve macrolide potency if we have a better understanding of their mode of action. Furthermore, a complete and detailed understanding of the mode of action of macrolides has remained vague, as new findings have challenged theories that are already in existence-due to this obscurity, research into macrolide modes of action continues to this day. CONCLUSION: In this review, we present an overview of macrolide antibiotics, with an emphasis on the latest knowledge regarding the mode of action of macrolides as well as the mechanisms of resistance employed by bacteria against macrolides.


Subject(s)
Anti-Bacterial Agents , Bacteria , Drug Resistance, Bacterial , Macrolides , Macrolides/pharmacology , Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Bacteria/genetics , Humans , Ribosomes/drug effects , Ribosomes/metabolism , Protein Biosynthesis/drug effects
9.
Mol Ther ; 32(9): 3145-3162, 2024 Sep 04.
Article in English | MEDLINE | ID: mdl-39097773

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) has a survival rate of 12%, and multiple clinical trials testing anti-PD-1 therapies against PDAC have failed, suggesting a need for a novel therapeutic strategy. In this study, we evaluated the potential of milbemycin oxime (MBO), an antiparasitic compound, as an immunomodulatory agent in PDAC. Our results show that MBO inhibited the growth of multiple PDAC cell lines by inducing apoptosis. In vivo studies showed that the oral administration of 5 mg/kg MBO inhibited PDAC tumor growth in both subcutaneous and orthotopic models by 49% and 56%, respectively. Additionally, MBO treatment significantly increased the survival of tumor-bearing mice by 27 days as compared to the control group. Interestingly, tumors from MBO-treated mice had increased infiltration of CD8+ T cells. Notably, depletion of CD8+ T cells significantly reduced the anti-tumor efficacy of MBO in mice. Furthermore, MBO significantly augmented the efficacy of anti-PD-1 therapy, and the combination treatment resulted in a greater proportion of active cytotoxic T cells within the tumor microenvironment. MBO was safe and well tolerated in all our preclinical toxicological studies. Overall, our study provides a new direction for the use of MBO against PDAC and highlights the potential of repurposing MBO for enhancing anti-PD-1 immunotherapy.


Subject(s)
CD8-Positive T-Lymphocytes , Carcinoma, Pancreatic Ductal , Pancreatic Neoplasms , Programmed Cell Death 1 Receptor , Tumor Microenvironment , Animals , Tumor Microenvironment/drug effects , Tumor Microenvironment/immunology , Mice , Humans , Cell Line, Tumor , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/immunology , Pancreatic Neoplasms/pathology , Programmed Cell Death 1 Receptor/antagonists & inhibitors , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/drug effects , Carcinoma, Pancreatic Ductal/drug therapy , Carcinoma, Pancreatic Ductal/immunology , Carcinoma, Pancreatic Ductal/pathology , Xenograft Model Antitumor Assays , Macrolides/pharmacology , Macrolides/therapeutic use , Apoptosis/drug effects , Cell Proliferation/drug effects , Immune Checkpoint Inhibitors/pharmacology , Immune Checkpoint Inhibitors/therapeutic use , Oximes/pharmacology , Disease Models, Animal , Female
10.
Int J Mol Sci ; 25(15)2024 Jul 29.
Article in English | MEDLINE | ID: mdl-39125836

ABSTRACT

Regulation of autophagy through the 62 kDa ubiquitin-binding protein/autophagosome cargo protein sequestosome 1 (p62/SQSTM1), whose level is generally inversely proportional to autophagy, is crucial in microglial functions. Since autophagy is involved in inflammatory mechanisms, we investigated the actions of pro-inflammatory lipopolysaccharide (LPS) and anti-inflammatory rosuvastatin (RST) in secondary microglial cultures with or without bafilomycin A1 (BAF) pretreatment, an antibiotic that potently inhibits autophagosome fusion with lysosomes. The levels of the microglia marker protein Iba1 and the autophagosome marker protein p62/SQSTM1 were quantified by Western blots, while the number of p62/SQSTM1 immunoreactive puncta was quantitatively analyzed using fluorescent immunocytochemistry. BAF pretreatment hampered microglial survival and decreased Iba1 protein level under all culturing conditions. Cytoplasmic p62/SQSTM1 level was increased in cultures treated with LPS+RST but reversed markedly when BAF+LPS+RST were applied together. Furthermore, the number of p62/SQSTM1 immunoreactive autophagosome puncta was significantly reduced when RST was used but increased significantly in BAF+RST-treated cultures, indicating a modulation of autophagic flux through reduction in p62/SQSTM1 degradation. These findings collectively indicate that the cytoplasmic level of p62/SQSTM1 protein and autophagocytotic flux are differentially regulated, regardless of pro- or anti-inflammatory state, and provide context for understanding the role of autophagy in microglial function in various inflammatory settings.


Subject(s)
Autophagosomes , Autophagy , Lipopolysaccharides , Macrolides , Microglia , Sequestosome-1 Protein , Animals , Sequestosome-1 Protein/metabolism , Microglia/metabolism , Microglia/drug effects , Macrolides/pharmacology , Autophagy/drug effects , Rats , Autophagosomes/metabolism , Autophagosomes/drug effects , Lipopolysaccharides/pharmacology , Cells, Cultured , Inflammation/metabolism , Biomarkers/metabolism
11.
Sci Rep ; 14(1): 19867, 2024 08 27.
Article in English | MEDLINE | ID: mdl-39191909

ABSTRACT

Drosophila suzukii lay eggs in soft-skinned, ripening fruits, making this insect a serious threat to berry production. Since its 2008 introduction into North America, growers have used insecticides, such as pyrethroids and spinosads, as the primary approach for D. suzukii management, resulting in development of insecticide resistance in this pest. This study sought to identify the molecular mechanisms conferring insecticide resistance in these populations. We sequenced the transcriptomes of two pyrethroid- and two spinosad-resistant isofemale lines. In both pyrethroid-resistant lines and one spinosad-resistant line, we identified overexpression of metabolic genes that are implicated in resistance in other insect pests. In the other spinosad-resistant line, we observed an overexpression of cuticular genes that have been linked to resistance. Our findings enabled the development of molecular diagnostics that we used to confirm persistence of insecticide resistance in California, U.S.A. To validate these findings, we leveraged D. melanogaster mutants with reduced expression of metabolic or cuticular genes that were found to be upregulated in resistant D. suzukii to demonstrate that these genes are involved in promoting resistance. This study is the first to characterize the molecular mechanisms of insecticide resistance in D. suzukii and provides insights into how current management practices can be optimized.


Subject(s)
Drosophila , Drug Combinations , Gene Expression Profiling , Insecticide Resistance , Insecticides , Macrolides , Pyrethrins , Animals , Insecticide Resistance/genetics , Macrolides/pharmacology , Pyrethrins/pharmacology , Drosophila/genetics , Insecticides/pharmacology , Transcriptome
12.
Article in English | MEDLINE | ID: mdl-39165019

ABSTRACT

Abstract: The Northern Territory (NT) has the highest rates of sexually transmitted infections (STI) in Australia; however, the local prevalence of Mycoplasma genitalium (M. genitalium) has not been previously determined. This study was designed to review M. genitalium detection, to determine the regional NT prevalence and macrolide resistance rates. In our study the NT background prevalence of M. genitalium is 13%, with the highest detection rates occurring in central Australia and in correctional facility inmates. Symptomatic patients attending sexual health clinics have a positivity rate of 12%, but very high macrolide resistance. The decision to screen for M. genitalium should be based on several factors, including the prevalence of the infection in the local population; the availability of effective treatments; and the potential benefits and risks of detection and therapy.


Subject(s)
Mycoplasma Infections , Mycoplasma genitalium , Humans , Mycoplasma genitalium/isolation & purification , Northern Territory/epidemiology , Mycoplasma Infections/epidemiology , Mycoplasma Infections/microbiology , Retrospective Studies , Prevalence , Male , Female , Adult , Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Middle Aged , Sexually Transmitted Diseases/epidemiology , Sexually Transmitted Diseases/microbiology , Young Adult , Macrolides/pharmacology
13.
Mar Drugs ; 22(8)2024 Jul 23.
Article in English | MEDLINE | ID: mdl-39195447

ABSTRACT

Two new compounds, macrolactin XY (1) and (5R, 9S, 10S)-5-(hydroxymethyl)-1,3,7-decatriene-9,10-diol (2), together with nine known compounds (3-11) were isolated from the marine Bacillus subtilis sp. 18 by the OSMAC strategy. These compounds were evaluated for antibacterial activity against six tested microorganisms. Compounds 1-5 and 7-10 showed varied antibacterial activity, with the minimum inhibitory concentration (MIC) ranging from 3 to 12 µg/mL. Macrolactin XY (1) was found to possess superior antibacterial activity, especially exhibiting significant effectiveness against Enterococcus faecalis. The antibacterial activity mechanism against E. faecalis was investigated. The mechanism may disrupt bacterial cell membrane integrity and permeability, and also inhibit the expression of genes associated with bacterial energy metabolism, as established by the experiments concerning cell membrane potential, SDS-PAGE electrophoresis, cell membrane integrity, and key gene expressions. This study offers valuable insights and serves as a theoretical foundation for the future development of macrolactins as antibacterial precursors.


Subject(s)
Anti-Bacterial Agents , Bacillus subtilis , Macrolides , Microbial Sensitivity Tests , Bacillus subtilis/drug effects , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/isolation & purification , Anti-Bacterial Agents/chemistry , Macrolides/pharmacology , Macrolides/isolation & purification , Macrolides/chemistry , Enterococcus faecalis/drug effects , Aquatic Organisms , Cell Membrane/drug effects
14.
Mediators Inflamm ; 2024: 4233439, 2024.
Article in English | MEDLINE | ID: mdl-39104632

ABSTRACT

Sepsis has been the leading cause of death in ICU patients. CD4+ T cells are the mainstay of the body's immune system, and the depletion of CD4+ T cells in sepsis is of great concern. Cytotoxic T lymphocyte-associated protein 4 (CTLA4) is a negative immunomodulator for T cell activation and degradation through the autophagy-lysosome pathway. Mammalian target of rapamycin (mTOR) is the most classical upstream regulator of autophagy. With a mouse model of sepsis through cecal ligation and puncture (CLP), T cell specific-mTOR/tuberous sclerosis complex 1 (TSC1)-knockout mice, and bafilomycin A1, a specific autophagosome-lysosome (A-L) fusion inhibitor, we primarily proved that mTOR could modulate the expression and accumulation of CTLA4 by regulating the onset process of autophagy such as A-L fusion. Given such a regulatory relationship, targeting mTOR could provide new light to improve immune function in sepsis, and the prospect of using rapamycin in the clinic would be worth exploring further.


Subject(s)
Autophagy , CD4-Positive T-Lymphocytes , CTLA-4 Antigen , Mice, Knockout , Sepsis , TOR Serine-Threonine Kinases , Animals , Sepsis/metabolism , Mice , CD4-Positive T-Lymphocytes/metabolism , CTLA-4 Antigen/metabolism , TOR Serine-Threonine Kinases/metabolism , Mice, Inbred C57BL , Macrolides/pharmacology , Male
15.
Front Cell Infect Microbiol ; 14: 1391879, 2024.
Article in English | MEDLINE | ID: mdl-39104851

ABSTRACT

This study aimed to investigate the bacterial characteristics of pneumococcal isolates obtained from a tertiary care hospital in Japan. We analyzed the antimicrobial susceptibility, possession of macrolide resistance genes, pneumococcal serogroup/serotype, and sequence type (ST) of pneumococcal isolates from patients aged 15 years or older between 2011 and 2020 at Nagasaki University Hospital. Of the 73 isolates analyzed, 86.3% showed resistance to macrolides, and 28.8%, 46.6%, and 11.0% harbored mefA, ermB, and both, respectively. Of the isolates possessing ermB, 97.6% showed high levels of macrolide resistance [minimal inhibitory concentration (MIC) range, > 16 µg/mL]. Solithromycin (MIC range, 0.03-0.25 µg/mL), regardless of the presence of macrolide resistance genes, and lascufloxacin (MIC range, 0.06-0.5 µg/mL) showed potent in vitro activity against pneumococci. Serotype 19A was the most prevalent (six isolates), followed by serotypes 10A, 15A, and 15B/C (five isolates each). Four serotypes (11A, 19A, 22F, and 23B) and five STs (36, 99, 433, 558, and 3111) were significantly correlated with the presence of macrolide resistance genes. All four isolates with serotype 11A/ST99 and three isolates with serotype 19A/ST3111 harbored both mefA and ermB. No macrolide resistance genes were detected in either of the two isolates with serotype 22F/ST433, while all ten isolates with serogroup 15 (serotypes 15A and 15B/C, five isolates each) possessed ermB alone. Our study revealed the bacterial characteristics of the pneumococcal isolates obtained from our hospital. In vitro activity of solithromycin and lascufloxacin against these isolates was confirmed.


Subject(s)
Anti-Bacterial Agents , Drug Resistance, Bacterial , Macrolides , Microbial Sensitivity Tests , Pneumococcal Infections , Serogroup , Streptococcus pneumoniae , Tertiary Care Centers , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/genetics , Streptococcus pneumoniae/isolation & purification , Streptococcus pneumoniae/classification , Humans , Pneumococcal Infections/microbiology , Japan , Anti-Bacterial Agents/pharmacology , Macrolides/pharmacology , Drug Resistance, Bacterial/genetics , Young Adult , Adolescent , Phenotype , Aged , Middle Aged , Adult , Bacterial Proteins/genetics , Female , Male , Methyltransferases/genetics , Aged, 80 and over , East Asian People , Membrane Proteins
16.
Euro Surveill ; 29(31)2024 Aug.
Article in English | MEDLINE | ID: mdl-39092529

ABSTRACT

As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive Bordetella pertussis qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced B. pertussis isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides. Pertussis resurgence may favour isolates that produce FIM2 and pertactin.


Subject(s)
Anti-Bacterial Agents , Bordetella pertussis , Macrolides , Whooping Cough , Bordetella pertussis/genetics , Bordetella pertussis/isolation & purification , Bordetella pertussis/drug effects , Humans , France/epidemiology , Macrolides/pharmacology , Whooping Cough/epidemiology , Whooping Cough/microbiology , Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Microbial Sensitivity Tests , Bacterial Outer Membrane Proteins/genetics , Whole Genome Sequencing , Virulence Factors, Bordetella/genetics , Genotype , Adult , Child , Incidence , Child, Preschool
17.
Bioorg Chem ; 151: 107712, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39146761

ABSTRACT

Ketolides (3-keto) such as TE-802 and acylides (3-O-acyl) like TEA0929 are ineffective against constitutively resistant pathogens harboring erythromycin ribosomal methylation (erm) genes. Following our previous work on alkylides (3-O-alkyl), we explored the structure-activity relationships of hybrids combining (R/S) 3-descladinosyl erythromycin with 6/7-quinolone motifs, featuring extended ether-linked spacers, with a focus on their efficacy against pathogens bearing constitutive erm gene resistance. Optimized compounds 17a and 31f not only reinstated efficacy against inducibly resistant pathogens but also demonstrated significantly augmented activities against constitutively resistant strains of Streptococcus pneumoniae and Streptococcus pyogenes, which are typically refractory to existing C-3 modified macrolides. Notably, hybrid 31f (coded ZN-51) represented a pioneering class of agents distinguished by its dual modes of action, with ribosomes as the primary target and topoisomerases as the secondary target. As a novel chemotype of macrolide-quinolone hybrids, alkylide 31f is a valuable addition to our armamentarium against macrolide-resistant bacteria.


Subject(s)
Anti-Bacterial Agents , Macrolides , Microbial Sensitivity Tests , Quinolones , Streptococcus pneumoniae , Structure-Activity Relationship , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/chemical synthesis , Quinolones/chemistry , Quinolones/pharmacology , Quinolones/chemical synthesis , Macrolides/chemistry , Macrolides/pharmacology , Streptococcus pneumoniae/drug effects , Molecular Structure , Drug Design , Streptococcus pyogenes/drug effects , Streptococcus pyogenes/enzymology , Dose-Response Relationship, Drug , Ethers/chemistry , Ethers/pharmacology , Ethers/chemical synthesis
18.
Biomed Pharmacother ; 177: 117105, 2024 Aug.
Article in English | MEDLINE | ID: mdl-39002438

ABSTRACT

Lung adenocarcinoma (LUAD) is the leading cause of cancer death worldwide, with high incidence and low survival rates. Nicotinic acetylcholine receptors play an important role in the progression of LUAD. In this study, a screening of 17 nicotinic acetylcholine receptor allosteric agents revealed that spinosad effectively suppressed the proliferation of LUAD cells. The experiments demonstrated that spinosad induced cell cycle arrest in the G1 phase and stimulated apoptosis, thereby impeding the growth of LUAD and enhancing the responsiveness to gefitinib in vitro and vivo. Mechanistic insights obtained through transcriptome sequencing, Co-IP, and protein immunoblots indicated that spinosad disrupted the interaction between CHRNA5 and EGFR, thereby inhibiting the formation of downstream complexes and activation of the EGFR signaling pathway. The supplementation of exogenous acetylcholine showed to mitigate the inhibition of LUAD cell proliferation induced by spinosad. This study elucidates the therapeutic effects and mechanisms of spinosad in LUAD, and offers a theoretical and experimental foundation for novel LUAD treatments.


Subject(s)
Adenocarcinoma of Lung , Apoptosis , Cell Proliferation , Drug Combinations , ErbB Receptors , Lung Neoplasms , Macrolides , Receptors, Nicotinic , Signal Transduction , Humans , Signal Transduction/drug effects , Cell Proliferation/drug effects , Receptors, Nicotinic/metabolism , ErbB Receptors/metabolism , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Lung Neoplasms/metabolism , Macrolides/pharmacology , Adenocarcinoma of Lung/drug therapy , Adenocarcinoma of Lung/pathology , Adenocarcinoma of Lung/metabolism , Adenocarcinoma of Lung/genetics , Animals , Apoptosis/drug effects , Cell Line, Tumor , Mice, Nude , Mice , Mice, Inbred BALB C , A549 Cells
19.
Emerg Infect Dis ; 30(8): 1692-1696, 2024 Aug.
Article in English | MEDLINE | ID: mdl-39043456

ABSTRACT

Before the COVID-19 pandemic, Mycoplasma pneumoniae infections emerged during spring to summer yearly in Taiwan, but infections were few during the pandemic. M. pneumoniae macrolide resistance soared to 85.7% in 2020 but declined to 0% during 2022-2023. Continued molecular surveillance is necessary to monitor trends in macrolide-resistant M. pneumoniae.


Subject(s)
Anti-Bacterial Agents , COVID-19 , Drug Resistance, Bacterial , Macrolides , Mycoplasma pneumoniae , Pneumonia, Mycoplasma , SARS-CoV-2 , Humans , Taiwan/epidemiology , Macrolides/pharmacology , Macrolides/therapeutic use , Mycoplasma pneumoniae/drug effects , Mycoplasma pneumoniae/genetics , Pneumonia, Mycoplasma/epidemiology , Pneumonia, Mycoplasma/drug therapy , Pneumonia, Mycoplasma/microbiology , COVID-19/epidemiology , Child , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Child, Preschool , Pandemics , Male , Female , Infant , Adolescent , Microbial Sensitivity Tests
20.
Sci Rep ; 14(1): 17463, 2024 07 29.
Article in English | MEDLINE | ID: mdl-39075238

ABSTRACT

Syphilis is a multistage sexually transmitted disease caused by Treponema pallidum ssp. pallidum. In the Czech Republic, there are around 700-800 new syphilis cases annually, continuously increasing since 2012. This study analyzed a total of 1228 samples from 2004 to 2022. Of the PCR-positive typeable samples (n = 415), 68.7% were fully-typed (FT), and 31.3% were partially-typed. Most of the identified isolates belonged to the SS14-clade and only 6.3% were the Nichols-like cluster. While in the beginning of sample collection isolates have been macrolide-susceptible, recent isolates are completely resistant to macrolides. Among the FT samples, 34 different allelic profiles (APs) were found. Most of the profiles (n = 27) appeared just once in the Czech population, while seven profiles were detected more than twice. The most frequent APs belonged to two separate groups of SS14-like isolates, including group of 1.3.1 (ST 1) and 1.26.1 (ST 25) profiles, and the second group containing 1.1.8 (ST 3), 1.1.1 (ST 2), and 1.1.3 (ST 11) (representing 57.5%, and 25.3% of all detected APs, respectively). Both groups consistently differed in 6 nucleotide positions in five genes (TP0150, TP0324, TP0515, TP0548, and TP0691) coding amino-acid replacements suggesting that one or more of these differences could be involved in the higher success of the first group.


Subject(s)
Alleles , Multilocus Sequence Typing , Syphilis , Treponema pallidum , Czech Republic , Humans , Treponema pallidum/genetics , Treponema pallidum/isolation & purification , Syphilis/microbiology , Syphilis/epidemiology , Syphilis/genetics , Male , Female , Adult , Macrolides/pharmacology , Middle Aged , Genotype
SELECTION OF CITATIONS
SEARCH DETAIL